Dysautonomia Research Registry: POTS, ME/CFS, and Dysautonomia Research Explained

The largest randomized drug trial run in POTS lowered heart rate with ivabradine and saw no improvement on the registered symptom endpoint. The arm that did improve symptoms was coordinated non-drug care.

A 2025 letter in Clinical Autonomic Research calls the NASA Lean Test an improper shortcut while endorsing the active stand as a screen for POTS. Both are screening tools, and the lean test is arguably the closer approximation of the tilt table.

Functional neurology gets called pseudoscience by people who cannot name a test it uses. Every test it runs in dysautonomia was invented by a mainstream physician, from the 1704 Valsalva maneuver to 1980s transcranial Doppler.

You should not be able to simply pass or fail a tilt table test. This paper defines a measurable subtype of OI in patients whose HR and BP look completely normal on standard testing.

Foundational for the CO₂ and perfusion conversation in OI testing, and the fact that it dates to 1998 tells you everything about how long this evidence has been ignored at the clinical level.

A review article that explains in plain, coherent logic why CO₂ monitoring belongs in modern orthostatic testing. Useful for making the case to a clinician.

Frames POTS and HYCH/OCHOS as overlapping rather than distinct, and makes a direct claim about what is actually driving the tachycardia in POTS patients.

An important counterweight. Not every case of orthostatic cerebral hypoperfusion is explained by hyperventilation and CO₂ dysregulation. Autoregulation itself can be impaired even in normocapnic POTS.